Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

• Status: Recruiting
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF). Participants will be 1:1 randomized into early or late initiation group. The primary endpoint is early neurological deterioration (END) before discharge.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Treatments: Anticoagulants

Criteria

Inclusion Criteria:

• Age > 18 years old

• Acute ischemic stroke with onset < 48 hours

• Have a history or newly diagnosed as NVAF

• NIHSS on admission <= 8

Exclusion Criteria:

• Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury

• Have a history or newly diagnosed as valvular heart disease

• Mural thrombus in heart

• Contraindications of anticoagulation therapy within 12 days after AIS, e.g. severe intracranial hemorrhage

• Received reperfusion therapy, e.g. intravenous thrombolysis and endovascular treatment

• Concomitant stenosis (>50%) of carotid artery/intracranial artery, of which the ischemic lesion located within the territory

• Life expectancy less than 1 year

• Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding

• Pregnant or lactating women

• Individuals identified by researchers as unsuitable for participation in the study due to other reasons.